Skip to main navigation Skip to search Skip to main content

Positive Impact of the Bionic Pancreas on Diabetes Control in Youth 6-17 Years Old with Type 1 Diabetes: A Multicenter Randomized Trial

  • Laurel H. Messer
  • , Bruce A. Buckingham
  • , Fran Cogen
  • , Mark Daniels
  • , Greg Forlenza
  • , Rabab Z. Jafri
  • , Nelly Mauras
  • , Andrew Muir
  • , R. Paul Wadwa
  • , Perrin C. White
  • , Steven J. Russell
  • , Edward R. Damiano
  • , Firas H. El-Khatib
  • , Katrina J. Ruedy
  • , Courtney A. Balliro
  • , Zoey Li
  • , Martin Chase Marak
  • , Peter Calhoun
  • , Roy W. Beck
  • University of Colorado Denver
  • Stanford University
  • Children's National Medical Center
  • University of California at Irvine
  • University of Texas Health Science Center at San Antonio
  • Emory University
  • University of Texas Southwestern Medical Center
  • Massachusetts General Hospital
  • Boston University
  • Beta Bionics
  • Jaeb Center for Health Research

Research output: Contribution to journal › Article › peer-review

54 Scopus citations

Abstract

Objective: To evaluate the insulin-only configuration of the iLet® bionic pancreas (BP) in youth 6-17 years old with type 1 diabetes (T1D). Research Design and Methods: In this multicenter, randomized, controlled trial, 165 youth with T1D (6-17 years old; baseline HbA1c 5.8%-12.2%; 35% using multiple daily injections, 36% using an insulin pump without automation, 4% using an insulin pump with low glucose suspend, and 25% using a hybrid closed-loop system before the study) were randomly assigned 2:1 to use BP (n = 112) with insulin aspart or insulin lispro (BP group) or to a control group (n = 53) using their personal standard care insulin delivery (SC group) plus real-time continuous glucose monitoring (CGM). The primary outcome was HbA1c at 13 weeks. Results: Mean HbA1c decreased from 8.1% ± 1.2% at baseline to 7.5% ± 0.7% at 13 weeks with BP versus 7.8% ± 1.1% at both baseline and 13 weeks with SC (adjusted difference =-0.5%, 95% CI-0.7% to-0.2%, P < 0.001). Participants with baseline HbA1c ≥9.0% (n = 34) decreased mean HbA1c from 9.7% ± 0.8% to 7.9% ± 0.6% after 13 weeks with BP compared with 9.7% ± 0.5% to 9.8% ± 0.8% with SC. Over 13 weeks, mean time in range (TIR) 70-180 mg/dL increased by 10% (2.4 h per day) and mean CGM glucose was reduced by 15 mg/dL with BP compared with SC (P < 0.001). Analyses of time >180 mg/dL, time >250 mg/dL, and standard deviation of CGM glucose favored BP (P < 0.001). Time <54 mg/dL was low at baseline (median 0.2%) and not significantly different between groups over 13 weeks (P = 0.24). A severe hypoglycemia event occurred in 3 (2.7%) participants in the BP group and in 1 (1.9%) in the SC group. Conclusions: In youth 6-17 years old with T1D, use of insulin-only configuration of BP improved HbA1c, TIR, and hyperglycemic metrics without increasing CGM-measured hypoglycemia compared with standard of care. Improvement in glycemic metrics was most pronounced in participants with high baseline HbA1c levels. Clinical Trial Registry: Clinicaltrials.gov; NCT04200313.

Original languageEnglish
Pages (from-to)712-725
Number of pages14
JournalDiabetes Technology and Therapeutics
Volume24
Issue number10
DOIs
StatePublished - 1 Oct 2022

Keywords

  • Artificial pancreas
  • Automated insulin delivery
  • Bionic pancreas
  • Evaluation
  • Pediatrics
  • Type 1 diabetes

Fingerprint

Dive into the research topics of 'Positive Impact of the Bionic Pancreas on Diabetes Control in Youth 6-17 Years Old with Type 1 Diabetes: A Multicenter Randomized Trial'. Together they form a unique fingerprint.

Cite this